Cencora signed an agreement with Kite, a Gilead company, to distribute Kite’s FDA-approved CAR T therapies Yescarta and Tecartus across the U.S. The partnership is designed to expand access at authorized treatment centers including health systems and community oncology practices. Cencora said it will leverage its specialty distribution infrastructure to reduce administrative burdens for providers as Kite continues to expand its network of authorized sites. For the cell therapy market, this type of logistics-and-service agreement can materially affect time-to-treatment by smoothing order management and coordination—areas that historically challenge community providers. The deal also reinforces that scaling CAR T uptake depends not only on clinical protocols but on distribution workflows and site enablement.